



DEFENSE  
HEALTH AGENCY

**MB&RS**

**OFFICE OF THE ASSISTANT SECRETARY OF DEFENSE  
HEALTH AFFAIRS  
16401 EAST CENTRETECH PARKWAY  
AURORA, CO 80011-9066**

**CHANGE 148  
6010.57-M  
DECEMBER 3, 2015**

**PUBLICATIONS SYSTEM CHANGE TRANSMITTAL  
FOR  
TRICARE POLICY MANUAL (TPM), FEBRUARY 2008**

The TRICARE Management Activity has authorized the following addition(s)/revision(s).

**CHANGE TITLE: PHARMACY WEBSITE UPDATES**

**CONREQ: 17511**

**PAGE CHANGE(S): See page 2.**

**SUMMARY OF CHANGE(S): This change updates obsolete web links to the Formulary Search Tool, TRICARE For Life Drug List, and Specialty Drug List.**

**EFFECTIVE DATE: December 3, 2015.**

**IMPLEMENTATION DATE: December 3, 2015.**

**This change is made in conjunction with Feb 2008 TOM, Change No. 158.**

FAZZINI.ANN.N  
OREEN.1199802  
271

Digitally signed by  
FAZZINI.ANN.NOREEN.1199802271  
DN: c=US, o=U.S. Government, ou=DoD,  
ou=PKI, ou=DHA,  
cn=FAZZINI.ANN.NOREEN.1199802271  
Date: 2015.11.30 12:36:09 -07'00'

**Ann N. Fazzini  
Team Chief, Medical Benefits &  
Reimbursement Section (MB&RS)  
Defense Health Agency (DHA)**

**ATTACHMENT(S): 4 PAGE(S)  
DISTRIBUTION: 6010.57-M**

**WHEN PRESCRIBED ACTION HAS BEEN TAKEN, FILE THIS TRANSMITTAL WITH BASIC DOCUMENT.**

**CHANGE 148**  
**6010.57-M**  
**DECEMBER 3, 2015**

**REMOVE PAGE(S)**

**CHAPTER 8**

Section 9.1, pages 1 - 4

**INSERT PAGE(S)**

Section 9.1, pages 1 - 4

## Chapter 8

## Section 9.1

# Pharmacy Benefits Program

Issue Date: August 2002

Authority: 32 CFR 199.2(b), 32 CFR 199.4(b)(2)(vi), (b)(3)(iii), (b)(5)(v), (d)(3)(vi), (e)(11)(i), 32 CFR 199.5(d)(12); 32 CFR 199.17, and 10 USC 1074g

---

### 1.0 DESCRIPTION

#### 1.1 General

The TRICARE Pharmacy (TPharm) benefit includes retail and mail order prescription services, medications provided by physicians and other appropriate clinicians, and pharmaceutical agents provided in support of home health care. TRICARE uses a number of contractors to administer the benefit.

#### 1.2 Retail Prescription Service

Retail pharmacy services, network and non-network, will be provided under a TPharm contract and will be subject to the Uniform Formulary. The TRICARE formulary is found at <http://www.tricare.mil/pharmacyformulary>. The retail pharmacy contractor is responsible for administering claims related to pharmaceuticals dispensed by an authorized provider with a National Council of Prescription Drug Programs (NCPDP) or other nationally recognized pharmacy designation.

#### 1.3 Mail Order Prescription Service

Mail order prescription services are provided under a TPharm contract and will be subject to the Uniform Formulary. The TRICARE formulary is found at <http://www.tricare.mil/pharmacyformulary>.

#### 1.4 Medical Claims That Include Pharmaceutical Agents

Pharmaceutical agents provided by physicians and other appropriate clinicians, and pharmaceutical agents provided in support of home health care are processed by the Managed Care Support Contractor(s) (MCSC). Claims for pharmaceutical agents (e.g., injectables) not appropriate for self-administration are the responsibility of the MCSC.

#### 1.5 Infusion Drug Therapy Delivered In The Home

When injectable and infusion drug therapy are medically necessary, and delivery and administration in the home is appropriate the MCSC shall provide prior authorization of injectable or infused drugs to a TRICARE authorized pharmacy in order for the pharmaceutical agent to be

fulfilled under the pharmacy benefit pursuant to [Section 20.1](#), "Infusion Drug Therapy Delivered in the Home".

## 1.6 Overseas Claims

The TRICARE overseas claims processor (see the TRICARE Operations Manual (TOM), [Chapter 24, Section 9](#)) processes pharmaceutical claims from most overseas locations. As of June 1, 2004, the TPharm contractor processes network and non-network retail pharmaceutical claims in Puerto Rico, the U.S. Virgin Islands, Northern Mariana Islands, and Guam.

## 2.0 POLICY

### 2.1 Formulary

Formulary management will be the responsibility of the Government as defined by [32 CFR 199.21](#), Pharmacy Benefits Program. This regulation establishes procedures for the inclusion of pharmaceutical agents on a Uniform Formulary based upon relative clinical effectiveness and cost effectiveness; establishes cost-sharing requirements, including a tiered copayment structure, for generic, formulary and non-formulary pharmaceutical agents; establishes procedures to assure the availability of pharmaceutical agents not included on the Uniform Formulary to eligible beneficiaries at the non-formulary cost-share tier; establishes procedures to provide, when clinically necessary, pharmaceutical agents not included on the Uniform Formulary under the same terms and conditions as an agent on the Uniform Formulary; establishes procedures to assure the availability of clinically appropriate non-formulary pharmaceutical agents to members of the uniformed services; establishes procedures for prior authorization when required; and establishes a Department of Defense Pharmacy and Therapeutics Committee (DoD P&T Committee) and a Uniform Formulary Beneficiary Advisory Panel. All formulary decisions, to include prior authorization requirements, designation of non-formulary agents, quantity limits, and other medication use policies will be communicated to all contractors who have responsibility for administering the pharmacy benefit.

### 2.2 General Prescription Coverage

**2.2.1** The Pharmacy Benefits Program generally requires mandatory substitution of generic drugs in accordance with [32 CFR 199.21\(j\)\(2\)](#). If state law prohibits generic substitution on drugs, the contractor, at the direction of the government, shall be able to process the brand product.

**2.2.2** Eligible beneficiaries shall pay a copayment for drug claims that are cost-shared under the Pharmacy Benefit Program in accordance with the TRICARE Reimbursement Manual (TRM), [Chapter 2, Addendum B](#).

**2.2.3** TRICARE is the secondary payor on claims where Other Health Insurance (OHI) coverage exists. OHI claims are reimbursed in accordance with TRM, [Chapter 4, Section 3](#). Reimbursement will be the lesser of the TRICARE allowed amount or the remaining amount after OHI payment.

**2.2.4** Labeled Indications. Pharmaceutical agents may be cost-shared when:

- The pharmaceutical agent is approved for marketing by the U.S. Food and Drug Administration (FDA);

- The pharmaceutical agent is prescribed by a provider, acting within the scope of his/her license, for its labeled indication; and
- The pharmaceutical agent is furnished by a provider in accordance with all applicable state laws and licensing requirements.

**2.2.5** Coverage may also be considered for off-label uses of drugs and biologics.

**2.2.5.1** Off-label drugs and biologics must meet the definition of Off-Label Use of a Drug or Device as described in 32 CFR 199.2:

Off-Label Use of a Drug or Device. A use other than an intended use for which the prescription drug, biologic or device is legally marketed under the Federal Food, Drug, and Cosmetic Act or the Public Health Services Act. This includes any use that is not included in the approved labeling for an approved drug, licensed biologic, approved device or combination product; any use that is not included in the cleared statement of intended use for a device that has been determined by the Food and Drug Administration (FDA) to be substantially equivalent to a legally marketed predicate device and cleared for marketing; and any use of a device for which a manufacturer or distributor would be required to seek pre-market review by the FDA in order to legally include that use in the device's labeling.

**2.2.5.2** Approval for reimbursement of off-label uses of drugs and biologics reimbursed by the medical program shall be provided by the MCSC. The MCSC may provide approval for the reimbursement of off-label uses when the off-label use is medically necessary and demonstrations from medical literature, national organizations, or technology assessment bodies show that the off-label use of the drug or biologic is safe, effective and in accordance with nationally accepted standards of practice in the medical community. If the drug is FDA approved and the off-label use is medically necessary, supported by medical literature identified by the MCSC, which indicates the drug is nationally accepted as standard practice, and is not otherwise excluded, the MCSC may approve the cost-sharing for the off-label drug. Drugs provided by the TRICARE Overseas Program (TOP) shall continue to follow the policies established in Chapter 12, TRICARE Operations Manual (TOM), Chapter 24, and the TOP contract.

**2.2.6** Pharmaceutical agents grandfathered by the Federal Food, Drug and Cosmetic Act of 1938 may be cost-shared as if FDA approved.

**2.2.7** Insulin and related supplies may be cost-shared for known diabetic patients, even though a prescription may not be required for purchase.

**2.2.8** Pharmaceutical agents with FDA "orphan drug" designation and marketing approval may be cost-shared when used in the treatment of a rare disease or condition. For the purpose of the Pharmacy Benefits Program, TRICARE adopts the FDA definition of the term "rare disease or condition."

**2.2.9** Legend vitamins may be cost-shared only when used as a specific treatment of a medical condition. In addition, prenatal vitamins that require a prescription in the United States may be cost-shared. Prenatal vitamins requiring a prescription are covered for prenatal care only.

## TRICARE Policy Manual 6010.57-M, February 1, 2008

### Chapter 8, Section 9.1

#### Pharmacy Benefits Program

---

**2.2.10** Pharmaceutical agents intended to promote smoking cessation, including legend and Over-The-Counter (OTC) drugs, may be cost-shared when approved by the Director, Defense Health Agency (DHA) for inclusion in the DoD Smoking Cessation Program, outlined in Public Law 110-417, section 713, when dispensed at the TRICARE Mail Order Pharmacy (TMOP) to beneficiaries deemed eligible under the aforementioned law.

**2.2.11** The DoD establishes quantity limits and prior authorizations for certain pharmaceutical agents. Prior authorization request forms, criteria, and list of pharmaceutical agents with established quantity limits are available at: <http://www.tricare.mil/pharmacyformulary>

**2.2.12** National Defense Authorization Act (NDAA) Fiscal Year (FY) 2015, Section 702 mandates beneficiaries to obtain select brand name maintenance medications from the TMOP or the Military Treatment Facility (MTF) pharmacy beginning October 1, 2015. Active Duty Service Members (ADSMs) are exempt. TOP TRICARE For Life (TFL) beneficiaries, with the exception of those beneficiaries residing in the U.S. territories, may not be eligible for this program. In order to be eligible they need to be residing in a country that allows use of TMOP, have prescriptions written by a U.S. licensed providers, and have an APO/FPO mailing address.

**2.2.12.1** Maintenance medications are defined as medications prescribed for a chronic, long-term condition that is taken on a regular, recurring basis. Those maintenance medications which are clinically appropriate and cost-effective to dispense at TMOP will be included in the program as select maintenance medications. Exceptions may be granted per the following guidelines.

**2.2.12.2** A refill is defined as either a subsequent filling of an original prescription under the same prescription number (or other authorization as the original prescription), or a new original prescription for the same medication, strength and form issued at or near the end date of an earlier prescription.

**2.2.12.3** DHA will establish, maintain, and periodically revise and update a list of select maintenance medications accessible at <http://www.health.mil/SelectDrugList> and by telephone through the pharmacy contractor's call center.

**2.2.12.4** The NDAA authorizes a waiver of the mail order requirement based on patient needs and other appropriate circumstances. This waiver is obtained through an administrative override request to the TRICARE pharmacy contractor under procedures established by the Director, DHA. There is a blanket waiver for prescription medications that are for acute care needs. There is also a blanket waiver for prescriptions covered by OHI. There is a case-by-case waiver to permit prescription maintenance medication refills at a retail pharmacy when necessary due to personal need or hardship, emergency, or other special circumstances (i.e., nursing home residents).

**2.2.12.5** The pharmacy contractor shall notify beneficiaries of the new rules and the mechanisms which will allow them to receive adequate medication during their transition to TMOP.

**2.2.12.6** The pharmacy contractor shall provide a toll free number to assist beneficiaries in transferring their prescriptions from retail pharmacies to TMOP.

**2.2.12.7** Beneficiaries shall be advised that they may receive up to two, 30-day fills at a retail pharmacy while they transition their prescription. The beneficiary shall be contacted after each of